share_log

康方生物:截至二零二四年三月三十一日止月份股份發行人的證券變動月報表

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 March 2024

香港交易所 ·  Apr 5 05:11
Summary by Moomoo AI
康方生物科技(開曼)有限公司於2024年4月5日向香港交易及結算所有限公司提交了最新的證券變動月報表,報告截至2024年3月31日的公司股份變動情況。報告顯示,公司的法定/註冊股本在3月份未有變動,結存維持在5,000,000,000股,每股面值0.00001美元,總額為50,000美元。此外,公司於2024年3月28日根據一般授權配售了24,800,000股新股份,每股價格為47.65港元,並於同月完成了所有相關的法律及上市程序。股份期權方面,公司於2022年6月28日採納的首次公開發售後購股權計劃下,本月內無新增股份期權,結存數目維持在450,000股。報告中未提及其他類型的證券變動。
康方生物科技(開曼)有限公司於2024年4月5日向香港交易及結算所有限公司提交了最新的證券變動月報表,報告截至2024年3月31日的公司股份變動情況。報告顯示,公司的法定/註冊股本在3月份未有變動,結存維持在5,000,000,000股,每股面值0.00001美元,總額為50,000美元。此外,公司於2024年3月28日根據一般授權配售了24,800,000股新股份,每股價格為47.65港元,並於同月完成了所有相關的法律及上市程序。股份期權方面,公司於2022年6月28日採納的首次公開發售後購股權計劃下,本月內無新增股份期權,結存數目維持在450,000股。報告中未提及其他類型的證券變動。
Kangfang Biotechnology (Cayman) Limited filed with Hong Kong Trading and Settlement Limited on 5 April 2024 with Hong Kong Trading and Settlement Limited, reporting the changes in the company's shares for the year ended 31 March 2024. The report showed that the company's regulated/registered share capital remained unchanged in March, holding 5,000,000,000 shares with a face value of $0.00001 per share for a total of $50,000. In addition, on 28 March 2024, the Company distributed 24,800,000 new shares under general authorisation at a price of HK$47.65 per share and completed all relevant legal and listing procedures in the same month. In terms of stock options, under the Company's initial public offering post-sale share option plan adopted on June 28, 2022, with no additional share options during the month and the number of deposits remained at 450,000 shares. Changes in other types of securities are not mentioned in the report.
Kangfang Biotechnology (Cayman) Limited filed with Hong Kong Trading and Settlement Limited on 5 April 2024 with Hong Kong Trading and Settlement Limited, reporting the changes in the company's shares for the year ended 31 March 2024. The report showed that the company's regulated/registered share capital remained unchanged in March, holding 5,000,000,000 shares with a face value of $0.00001 per share for a total of $50,000. In addition, on 28 March 2024, the Company distributed 24,800,000 new shares under general authorisation at a price of HK$47.65 per share and completed all relevant legal and listing procedures in the same month. In terms of stock options, under the Company's initial public offering post-sale share option plan adopted on June 28, 2022, with no additional share options during the month and the number of deposits remained at 450,000 shares. Changes in other types of securities are not mentioned in the report.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more